YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)


AddThis Social Bookmark Button

Injured by Vioxx?

Parker Waichman Alonso LLP Has Been Representing Vioxx Heart Attack & Stroke Victims Nationwide Since 2001. Merck & Co. removed its blockbuster arthritis drug Vioxx (Generic: Rofecoxib) from the market worldwide because new data from a clinical trial found an increased risk of heart attack and stroke. Merck decided to remove the drug from the market on September 30, 2004, after data from the trial showed an increased risk of heart attack, stroke, blood clots and other cardiovascular complications. Parker & Waichman has been the choice for Vioxx victims in need of a pharmaceutical liability lawyer since 2001.

Vioxx Recall Timeline
Lancet Says Vioxx Should Have Been Recalled in 2000
Documents May Show Merck Knew About Vioxx Side Effects

The data comes from a three-year study aimed at showing that Vioxx at a 25 milligram dose prevents recurrence of polyps in the colon and rectum. The trial was stopped after Merck discovered the higher heart risk compared to patients taking dummy pills.

Before the withdrawal of Vioxx, the FDA announced that patients taking Vioxx have a 50 percent greater chance of heart attacks and sudden cardiac death. he study, presented at an epidemiologists conference, also found patients taking the highest recommended daily dosage of Vioxx had three times the risk of heart attack and sudden cardiac death as those not taking standard painkillers.

The popular and heavily advertised arthritis drugs Vioxx and Celebrex have been linked by researchers to an increase in the risk of blood clots, heart attacks and strokes.The study from the Cleveland Clinic appeared in the Journal of the American Medical Association and was based on an analysis of previous clinical trials. Celebrex and Vioxx are projected to produce U.S. sales greater than $6 billion this year.

In a study of more than 8,000 patients that compared the COX-2 inhibitor rofecoxib Vioxx) with the traditional NSAID naproxen, the risk of cardiovascular problems, including heart attack,chest pain related to heart disease, stroke, sudden death and blood clots, was more than two times higher in the rofecoxib group than in the naproxen group.

Vioxx, like Celebrex,  is classified as a COX-2 inhibitor, or coxib. COX-2 inhibitors, like older drugs such as ibuprofen and naproxen, are nonsteroidal anti-inflammatory drugs, or NSAIDs. Older NSAIDs reduce inflammation by blocking an enzyme called COX-2, but they also block another enzyme called COX-1. This enzyme helps protect the lining of the stomach, so blocking COX-2 can cause stomach irritation. COX-2 inhibitors only block COX-2, leaving the stomach-protecting COX-1 alone.

In 2000, Merck spent $160.8 million on direct to consumer Vioxx marketing. Many people are familiar with Vioxx television advertisements featuring the famous figure skater Dorothy Hamill. Sid Wolfe, a physician and director of the Health Research Group of the advocacy group Public Citizen in Washington, D.C. said "Dorothy Hamill doesn't tell people they have a four times higher risk of a heart attack on Vioxx."

If you or a loved one took Vioxx and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney.

Vioxx, Celebrex, Other Painkillers Up Risks for Heart Failure, Heart Attack Patients

Nov 12, 2008 | Parker Waichman Alonso LLP
Vioxx, Celebrex, ibuprofen and other NSAID painkillers increase the chances that heart attack and heart failure patients will experience a second heart attack or death, a new study says.  According to Danish researchers, the risk of a second heart attack or death actually doubled within the first 90 days of starting Vioxx or Celebrex.  Other painkillers, like ibuprofen, increased the risk between 2.1 and 1.3 times. The study was presented this week at the American Heart Association...

COX-2 Inhibitors More Likely to Raise Heart Risks Than Other NSAIDs

Nov 5, 2008 | Parker Waichman Alonso LLP
A new study that confirms the heart risks associated with a class of drugs called NSAIDs has found that the increased risk correlates to the specific pain-causing molecule they act against.   According to the study, NSAIDS that are cox-2 inhibitors are more likely to increase the risks of heart attacks and strokes. NSAIDs  are the most prescribed medications for treating conditions such as arthritis. Most people are familiar with over-the-counter, nonprescription NSAIDs, such as...

Pfizer Announces Bextra, Celebrex Settlement

Oct 17, 2008 | Parker Waichman Alonso LLP
Pfizer has reached a tentative agreement to settle lawsuits involving its Bextra and Celebrex painkillers for  $894 million.  If it goes forward, the Pfizer Bextra and Celebrex settlement will resolve roughly 90 percent of the personal injury lawsuits the company faces because of the drugs.Celebrex and Bextra are COX-2 inhibitors, a class of drugs that also includes Merck’s recalled Vioxx.  Such medications are linked to an increased risk of blood clots, heart attacks and...

Vioxx Heart Risks Long-Lasting

Oct 14, 2008 | Parker Waichman Alonso LLP
Heart risks from Vioxx, the defective painkiller pulled from the market in 2004, lingered long after many patients stopped taking the drug.  According to a report in The Washington Post, a study conducted by researchers at the M.D. Anderson Cancer Center in Houston, TX found that Vioxx increased the risk of heart attack and stroke by "close to twofold, and the risk persisted for approximately a year". The authors of the study, which was published online by the journal Lancet,...

Florida AG Sues Merck for Misleading Marketing

Oct 1, 2008 | Parker Waichman Alonso LLP
Earlier this week, Florida Attorney General Bill McCollum sued Merck and Company, Inc. for damages caused by the company’s allegedly deceptive marketing and promotion of its prescription drug, Vioxx.  The lawsuit states that Merck repeatedly failed to disclose Vioxx’s adverse effects while offering it to Florida’s Medicaid program as a safe painkiller.  The Attorney General’s office is charging the Merck violated Florida’s Deceptive and Unfair Trade...

More Vioxx News

Vioxx
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

What condition was this medication prescribed to treat?

What dosage were you prescribed daily?

Have any of the following side effects occurred? (Please check all that apply.)






Please further describe side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Contact
Statement of Clients' Rights | Site Map | ReNu with MoistureLoc | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Personal Injury Lawyer | Fusarium Keratitis | Stevens Johnson Syndrome

© 2002-2008 YourLawyer.com. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising

Parker Waichman Personal Injury News